细胞因子诱导的杀伤细胞治疗转移性肾癌的效果观察  

Clinical efficacy of CIK cell therapy in metastatic renal cell carcinoma

作　　者：刘雨晴[1] 贾建伟[1] 姚毅波[1] 

机构地区：[1]新乡医学院第三附属医院肿瘤科,河南新乡453003

出　　处：《河南医学研究》2017年第16期2906-2907,共2页Henan Medical Research

摘　　要：目的探究自体细胞因子诱导的杀伤细胞(CIK细胞)治疗转移性肾癌(MRCC)的临床效果和安全性评价。方法选取2010年3月1日至2013年3月15日新乡医学院第三附属医院收治的MRCC患者35例进行回顾性分析,分为单一组18例,予以单纯CIK细胞治疗,联合组17例,予以CIK细胞联合吉西他滨化疗。观察对比两组的疾病控制率、1年生存率及不良反应发生情况。结果单一组和联合组的疾病控制率(DCR)分别为67%和82%,1年生存率分别为72%和94%,差异均无统计学意义(P>0.05);单一组和联合组的不良反应发生率分别为17%和18%,差异无统计学意义(P>0.05)。结论 CIK细胞单纯应用或与化疗联合应用治疗MRCC均效果显著,安全性高,值得临床推广应用。Objective To explore the efficacy and safety of CIK cell therapy in metastatic renal cell carcinoma( MRCC).Methods Thirty-five patients with MRCC who were admitted to the Third Affiliated Hospital of Xinxiang Medical College from March 1 of 2010 to March 15 of 2013 were retrospectively analyzed. The patients were divided into a single group of 18 patients,treated with CIK cells alone,the cornbined group of 17 patients,treated with CIK cells and gemcitabine chemotherapy. The disease control rate,1-year survival rate and adverse reaction were compared in the two groups. Results The rates of disease control( DCR) were 67% and 82% in the single and combined groups,respectively,and the 1-year survival rates were 72% and 94%,respectively. There was no significant difference( P > 0. 05). The incidences of adverse reactions were 17% and 18% in the single group and the combined group,respectively,and the difference was not statistically significant( P>0. 05).Conclusion CIK cells alone or in combination with chemotherapy in the treatment of MRCC are effective,safe,worthy of clinical application.

关 键 词：转移性肾癌 化疗 CIK细胞 

分 类 号：R730.54[医药卫生—肿瘤]